Not all participating investigators were informed of new observations discovered by or reported to the sponsor.
Inspection Record
Immunomedics, Inc. — FDA 483 Findings
Inspectors Peter R LenahanThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Electronic records are used, but they do not meet systems validation and audit trail requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.
Failure to ensure proper monitoring ofthe study and ensure the study is conducted in accordance with the protocol and/or investigational plan.
The immediate package of the investigational new drug does not bear a label with the statement "Caution: New Drug- Limited by Federal (or United States) law to investigational use
A record as of the US FDA document published on 2019-04-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.